Skip to main content
Premium Trial:

Request an Annual Quote

TB Biosciences Raises $1.5M in Series A Financing

NEW YORK (GenomeWeb News) – TB Biosciences, which is developing a point-of-care test for the detection of tuberculosis, said today it has closed on its Series A financing round, raising $1.5 million.

The financing will be used to support product development and clinical trials.

Originate Ventures led the round, which also included investors Ben Franklin Technology Partners of Northeastern Pennsylvania and the NYU Innovation Venture Fund. With recent funding from the National Institutes of Health, new funds total $2.5 million, the Bethlehem, Penn.-based company said.

TB Bio is developing a point-of-care test based on proteins that are present in humans with active TB, but not in patients with latent TB or people who don't have TB. The proteins were discovered through a genomic analysis of the tuberculosis bacteria, and the company is working to combine them with derived synthetic peptides into a multiplexed diagnostic format, it said on its website.

The test would be used in TB control programs in endemic countries, while in the US it would be used as an adjunct to rapidly identify active TB in high-risk populations, such as immigrants from certain areas where the disease is common, as well as in veterans returning from such regions.

The market for the test also would include prisons and homeless shelters, TB Bio said.

Preliminary data using samples from endemic nations has shown sensitivity of greater than 90 percent for the test, Sam Niedbala, CEO and co-founder of TB Bio said.

"Careful screening of expressed proteins has unlocked a powerful library of critical peptides, which will enable the company to target those with active tuberculosis in children, adults, and those co-infected with HIV," he said in a statement.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.